Targeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug

Brain

Volumn 138, Issue 2, 2015, Pages 371-387

  Doeser, Anna ^a   Dickhof, Gesa ^a   Reitze, Margit ^a   Uebachs, Mischa ^a   Schaub, Christina ^a   Pires, Nuno Miguel ^b   Bonifácio, Maria Joaõ ^b   Soares Da Silva, Patrício ^b,c   Beck, Heinz ^a,d  

^a UNIVERSITY OF BONN   (Germany)

^b DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

Anticonvulsant drugs; Antiepileptogenesis; Epilepsy; Eslicarbazepine; Pharmacoresistance

Indexed keywords

ANTICONVULSIVE AGENT; CALCIUM CHANNEL T TYPE; CARBAMAZEPINE; ESLICARBAZEPINE; ESLICARBAZEPINE ACETATE; PILOCARPINE; VOLTAGE GATED CALCIUM CHANNEL; CONVULSANT AGENT; DIBENZAZEPINE DERIVATIVE; SCOPOLAMINE BROMIDE;

ADOLESCENT; ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; ELECTROENCEPHALOGRAM; EPILEPSY; EPILEPTOGENESIS; HIPPOCAMPUS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MOSSY FIBER; MOUSE; NEUROPATHOLOGY; NEWBORN; NONHUMAN; PATCH CLAMP TECHNIQUE; PRESCHOOL CHILD; PRIORITY JOURNAL; RAT; REFRACTORY TEMPORAL LOBE EPILEPSY; SCHOOL CHILD; SEIZURE; YOUNG ADULT; ANIMAL; BODY EQUILIBRIUM; CHEMICALLY INDUCED; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; IN VITRO STUDY; PATHOPHYSIOLOGY; WISTAR RAT;

ADOLESCENT; ADULT; ANIMALS; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; CHO CELLS; CONVULSANTS; CRICETULUS; DIBENZAZEPINES; EPILEPSY; HIPPOCAMPUS; HUMANS; IN VITRO TECHNIQUES; MALE; MICE; MIDDLE AGED; PILOCARPINE; POSTURAL BALANCE; RATS; RATS, WISTAR; SCOPOLAMINE HYDROBROMIDE; YOUNG ADULT;

EID: 84922369135     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awu339     Document Type: Article

References (35)

1. Albayram O, Alferink J, Pitsch J, Piyanova A, Neitzert K, Poppensieker K, et al. Role of CB1 cannabinoid receptors on GABAergic neurons in brain aging. Proc Natl Acad Sci USA 2011; 108: 11256-61.
2. Araú jo IM, Ambró sio AF, Leal EC, Verdasca MJ, Malva JO, Soares-da-Silva P, et al. Neurotoxicity induced by antiepileptic drugs in cultured hippocampal neurons: a comparative study between carbamazepine, oxcarbazepine, and two new putative antiepileptic drugs, BIA 2-024 and BIA 2-093. Epilepsia 2004; 45: 1498-505.
3. Banay-Schwartz M, Kenessey A, DeGuzman T, Lajtha A, Palkovits M. Protein content of various regions of rat brain and adult and aging human brain. Age 1992; 15: 51-4.
4. Becker AJ, Pitsch J, Sochivko D, Opitz T, Staniek M, Chen C-C, et al. Transcriptional upregulation of Cav3.2 mediates epileptogenesis in the pilocarpine model of epilepsy. J Neurosci Off J Soc Neurosci 2008; 28: 13341-53.
5. Ben-Menachem E, Gabbai AA, Hufnagel A, Maia J, Almeida L, Soares-da-Silva P. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res 2010; 89: 278-85.
6. Bernard C, Anderson A, Becker A, Poolos NP, Beck H, Johnston D. Acquired dendritic channelopathy in temporal lobe epilepsy. Science 2004; 305: 532-5.
7. Bialer M, Soares-da-Silva P. Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia 2012; 53: 935-46.
8. Doeser A, Soares-da-Silva P, Beck H, Uebachs M. The effects of eslicarbazepine on persistent Na( + ) current and the role of the Na( + ) channel b subunits. Epilepsy Res 2014; 108: 202-11.
9. Dunham NW, Miya TS. A note on a simple apparatus for detecting neurological deficit in rats and mice. J Am Pharm Assoc Am Pharm Assoc 1957; 46: 208-9.
10. Elger C, Bialer M, Cramer JA, Maia J, Almeida L, Soares-da-Silva P. Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia 2007; 48: 497-504.
11. Elger C, Halá sz P, Maia J, Almeida L, Soares-da-Silva P. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia 2009; 50: 454-63.
12. Elger C, Bialer M, Falcao A, Vaz-da-Silva M, Nunes T, Almeida L, et al. Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers. Epilepsia 2013; 54: 1453-61.
13. Gil-Nagel A, Lopes-Lima J, Almeida L, Maia J, Soares-da-Silva P. Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol Scand 2009; 120: 281-7.
14. Gil-Nagel A, Elger C, Ben-Menachem E, Halá sz P, Lopes-Lima J, Gabbai AA, et al. Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies. Epilepsia 2013; 54: 98-107.
15. Halá sz P, Cramer JA, Hodoba D, Czlonkowska A, Guekht A, Maia J, et al. Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy. Epilepsia 2010; 51: 1963-9.
16. Holm IE, Geneser FA. Histochemical demonstration of zinc in the hippocampal region of the domestic pig: II. Subiculum and hippocampus. J Comp Neurol 1991; 305: 71-82.
17. Jandová K, Pä sler D, Antonio LL, Raue C, Ji S, Njunting M, et al. Carbamazepine-resistance in the epileptic dentate gyrus of human hippocampal slices. Brain J Neurol 2006; 129: 3290-306.
18. Jimenez-Mateos EM, Engel T, Merino-Serrais P, McKiernan RC, Tanaka K, Mouri G, et al. Silencing microRNA-134 produces neuroprotective and prolonged seizure-suppressive effects. Nat Med 2012; 18: 1087-94.
19. Kö hling R. Voltage-gated sodium channels in epilepsy. Epilepsia 2002; 43: 1278-95.
20. Lö scher W, Brandt C. Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research. Pharmacol Rev 2010; 62: 668-700.
21. Loureiro AI, Fernandes-Lopes C, Wright LC, Soares-da-Silva P. Development and validation of an enantioselective liquidchromatography/ tandem mass spectrometry method for the separation and quantification of eslicarbazepine acetate, eslicarbazepine, R-licarbazepine and oxcarbazepine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879: 2611-18.
22. Magistretti J, Alonso A. Biophysical properties and slow voltage-dependent inactivation of a sustained sodium current in entorhinal cortex layer-II principal neurons: a whole-cell and single-channel study. J Gen Physiol 1999; 114: 491-509.
23. Perucca E, Elger C, Halá sz P, Falcao A, Almeida L, Soares-da-Silva P. Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. Epilepsy Res 2011; 96: 132-9.
24. Pitkänen A. Therapeutic approaches to epileptogenesis-hope on the horizon. Epilepsia 2010; 51(Suppl 3): 2-17.
25. Pitkänen A, Lukasiuk K. Mechanisms of epileptogenesis and potential treatment targets. Lancet Neurol 2011; 10: 173-86.
26. Pitkänen A, Nehlig A, Brooks-Kayal AR, Dudek FE, Friedman D, Galanopoulou AS, et al. Issues related to development of antiepileptogenic therapies. Epilepsia 2013; 54(Suppl 4): 35-43.
27. Pratt JH, Berry JF, Kaye B, Goetz FC. Lipid class and fatty acid composition of rat brain and sciatic nerve in alloxan diabetes. Diabetes 1969; 18: 556-61.
28. Rambeck B, Jü rgens UH, May TW, Pannek HW, Behne F, Ebner A, et al. Comparison of brain extracellular fluid, brain tissue, cerebrospinal fluid, and serum concentrations of antiepileptic drugs measured intraoperatively in patients with intractable epilepsy. Epilepsia 2006; 47: 681-94.
29. Remy S, Gabriel S, Urban BW, Dietrich D, Lehmann TN, Elger CE, et al. A novel mechanism underlying drug resistance in chronic epilepsy. Ann Neurol 2003a; 53: 469-79.
30. Remy S, Urban BW, Elger CE, Beck H. Anticonvulsant pharmacology of voltage-gated Na+ channels in hippocampal neurons of control and chronically epileptic rats. Eur J Neurosci 2003b; 17: 2648-58.
31. Sekerli M, Del Negro CA, Lee RH, Butera RJ. Estimating action potential thresholds from neuronal time-series: new metrics and evaluation of methodologies. IEEE Trans Biomed Eng 2004; 51: 1665-72.
32. Su H, Sochivko D, Becker A, Chen J, Jiang Y, Yaari Y, et al. Upregulation of a T-type Ca2 + channel causes a long-lasting modification of neuronal firing mode after status epilepticus. J Neurosci Off J Soc Neurosci 2002; 22: 3645-55.
33. Tauck DL, Nadler JV. Evidence of functional mossy fiber sprouting in hippocampal formation of kainic acid-treated rats. J Neurosci Off J Soc Neurosci 1985; 5: 1016-22.
34. Uebachs M, Opitz T, Royeck M, Dickhof G, Horstmann M-T, Isom LL, et al. Efficacy loss of the anticonvulsant carbamazepine in mice lacking sodium channel beta subunits via paradoxical effects on persistent sodium currents. J Neurosci Off J Soc Neurosci 2010; 30: 8489-501.
35. Weiergräber M, Henry M, Hescheler J, Smyth N, Schneider T. Electrocorticographic and deep intracerebral EEG recording in mice using a telemetry system. Brain Res Brain Res Protoc 2005; 14: 154-64